• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    WNBA Star Napheesa Collier Joins Team Opill® for Candid Conversations on Women's Health

    10/15/24 8:00:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRGO alert in real time by email
    • Opill® and Collier will hit the road to talk to women about their reproductive health options.

    GRAND RAPIDS, Mich., Oct. 15, 2024 /PRNewswire/ -- Today, Opill®—the first and only daily birth control pill available without a prescription in the U.S.—announces the launch of its partnership with WNBA Star and two-time Olympic Gold Medalist Napheesa Collier. The collaboration builds on Opill's multi-year partnership with the Women's National Basketball Association (WNBA).

    (PRNewsfoto/Perrigo Company plc)

    "One of the reasons Opill partnered with the WNBA is because the players are so passionate about using their platform to champion causes they believe in," said Leila Bahbah, Perrigo U.S. Women's Health Brand Lead. "Napheesa exudes that passion, and together we plan to educate and empower people to take charge of their reproductive health".

    Collier - an Olympic Gold Medalist, starting forward for the Minnesota Lynx, and a mother - is an advocate for women, and says that she's ready for the conversations, even if they're difficult.

     "It is important, especially now, to talk to women about their options when it comes to reproductive health," said Collier. "I am ready to get out there and have these very important conversations, and to help women learn about accessing the birth control that's right for them, including Opill."

    Collier was most recently named the Kia 2024 WNBA Defensive Player of the Year and finished second in MVP voting. Her resume also includes the 2019 Kia WNBA Rookie of the Year award, and four AT&T WNBA All-Star selections in addition to those two Olympic gold medals as part of Team USA. She says, however, that her greatest achievement is becoming a mother, and that one reason she was eager to partner with Opill was to make the world better for her daughter, Mila. 

    "I don't take for granted the opportunity to be part of positive change now that will continue to impact the next generation. I am proud to play a part in helping women get access to birth control if they want it."

    As part of the partnership, Collier will hit the road with Opill® in support of the brand's efforts to reach students on college campuses nationwide. These educational events will aim to increase awareness about the availability of Opill® and educate students on reproductive health and the importance of safe, effective and affordable contraception in the U.S.

    Opill®, developed by Perrigo, is the first daily birth control pill available without a prescription in the U.S. This landmark development represents a significant step forward in women's healthcare, providing a convenient and accessible option for contraception. With Opill®, women no longer need to visit a healthcare provider for a prescription, making it easier than ever to take control of their reproductive health.

    To learn more about Opill®, visit Opill.com or follow @opill_OTC on Instagram, TikTok, Facebook, Threads and X.

    About Opill®

    Opill® is the first ever and only over-the-counter birth control pill available in the United States. It is a progestin-only daily oral contraceptive that's safe and effective when used as directed to help prevent pregnancy. Do not use Opill® if you have or ever had breast cancer. See Opill® Drug Facts label for list of warnings. Opill® is not an emergency contraceptive (morning after pill) and won't prevent pregnancy when used after unprotected sex. It also doesn't protect against HIV/AIDS or other sexually transmitted diseases (STDs). For more information, please visit www.opill.com or follow @opill_OTC on Instagram, TikTok, Facebook, Threads and X.

    About Perrigo

    Perrigo Company plc (NYSE:PRGO), is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at www.perrigo.com. 

    Contact

    Media:

    All Opill®-related media inquiries to be directed to: [email protected] 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/wnba-star-napheesa-collier-joins-team-opill-for-candid-conversations-on-womens-health-302275871.html

    SOURCE Perrigo Company plc

    Get the next $PRGO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRGO

    DatePrice TargetRatingAnalyst
    1/14/2025Buy → Hold
    Argus
    1/6/2025$34.00 → $27.00Overweight → Neutral
    Piper Sandler
    9/24/2024$50.00 → $30.00Hold
    Jefferies
    11/17/2023$37.00Overweight
    Piper Sandler
    3/7/2023$49.00Buy
    Canaccord Genuity
    9/14/2022$46.00Hold → Buy
    Argus
    9/6/2022$48.00 → $54.00Equal Weight → Overweight
    Wells Fargo
    11/11/2021$59.00 → $55.00Outperform
    Raymond James
    More analyst ratings

    $PRGO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Perrigo to Release Third Quarter 2025 Financial Results on November 5, 2025

    DUBLIN, Oct. 22, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its third quarter 2025 financial results on Wednesday, November 5th, 2025, and host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 03742. A taped repla

    10/22/25 8:30:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opill® Nails It with First-Ever Brand Collaboration, Launching 'Opill and Chill' With Chillhouse

    Brands Will Donate One Pack of Opill® to NY Birth Control Access Project for Each Opill®-Themed Chill Tips Set Sold GRAND RAPIDS, Mich., Oct. 9, 2025 /PRNewswire/ -- Today, Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, announced that Opill® — the first and only daily birth control pill available without a prescription in the U.S. —is partnering with self-care brand Chillhouse to launch 'Opill and Chill,' empowering women to make self-care a priority. Opill® and Chillhouse are teaming up on a shared mission: to make wellness from the inside out accessible, empowering and stigma-free.

    10/9/25 8:00:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo to Attend Barclays 18th Annual Global Consumer Staples Conference

    DUBLIN, Aug. 20, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to participate in one-on-one investor meetings at the Barclays Global Consumer Staples Conference on Wednesday, September 3rd, 2025. About Perrigo   Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pio

    8/20/25 7:30:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 13, 2023 - FDA Approves First Nonprescription Daily Oral Contraceptive

    For Immediate Release: July 13, 2023 Today, the U.S. Food and Drug Administration approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy— the first daily oral contraceptive approved for use in the U.S. without a prescription. Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stor

    7/13/23 8:32:15 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Leadership Updates

    Live Leadership Updates

    View All

    Perrigo Announces Global Operations and Supply Chain Leadership Transition

    Ron Janish, EVP Global Operations and Supply Chain, to Retire Industry Veteran, Matt Winterman, Appointed EVP Product Supply, Operations Strategy & Transformation Officer DUBLIN, June 4, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Matt Winterman as Executive Vice President, Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025. Mr. Winterman succeeds Ron Janish, who will retire from the Company on September 30, 2025, following a distinguished career at Perrigo spanning more than two decades. Both executives will closely work together to ensure a smooth tran

    6/4/25 8:30:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer

    Expanded Scientific Office Unifies Scientific-Focused Teams, Facilitating Seamless Collaboration Across Product Portfolio Lennox Most Recently Led Regulatory, Medical Affairs, Safety and Quality Teams, Plus Drove Product Innovation, at Bayer Consumer Health Previous Chief Scientific Officer, Alison Ives, to Lead Newly Formed Disruptive Growth Team DUBLIN, Jan. 6, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the expansion of its Chief Scientific Office by uniting and integrating all global quality, pharmacovigilance, patient safety, regulatory affairs and innovation teams, enhancing organizational agility and s

    1/6/25 8:00:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Appoints Industry Veteran, Charles Atkinson, as Executive Vice President, General Counsel and Secretary

    Atkinson joins Perrigo from Haleon plc, where he previously served as Interim General Counsel DUBLIN, Sept. 4, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Charles Atkinson as Executive Vice President, General Counsel and Secretary. He is a skilled lawyer with nearly 25 years of experience, mostly within the regulated consumer self-care industry. President and CEO Patrick Lockwood-Taylor commented, "I am very excited to welcome Charles to the Perrigo leadership team. His strat

    9/4/24 8:00:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and CSO Lennox Abigail bought $28,125 worth of Ordinary Shares (1,255 units at $22.41) (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    9/10/25 4:19:48 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, General Counsel & Sec. Atkinson Charles bought $23,200 worth of Ordinary Shares (1,000 units at $23.20) (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    9/9/25 3:47:36 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & CHRO Willis Robert bought $35,858 worth of Ordinary Shares (1,488 units at $24.10), increasing direct ownership by 4% to 41,939 units (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    8/22/25 1:27:37 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by EVP, Supply, Ops, Strategy Winterman Matthew John

    4 - PERRIGO Co plc (0001585364) (Issuer)

    9/16/25 4:06:34 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Parker Geoffrey M.

    4 - PERRIGO Co plc (0001585364) (Issuer)

    9/16/25 12:16:53 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Alford Bradley A

    4 - PERRIGO Co plc (0001585364) (Issuer)

    9/16/25 12:12:02 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Perrigo downgraded by Argus

    Argus downgraded Perrigo from Buy to Hold

    1/14/25 8:38:48 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Perrigo from Overweight to Neutral and set a new price target of $27.00 from $34.00 previously

    1/6/25 8:24:36 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Perrigo with a new price target

    Jefferies resumed coverage of Perrigo with a rating of Hold and set a new price target of $30.00 from $50.00 previously

    9/24/24 8:23:03 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Perrigo Company plc

    SCHEDULE 13G - PERRIGO Co plc (0001585364) (Subject)

    8/11/25 7:57:37 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Perrigo Company plc

    10-Q - PERRIGO Co plc (0001585364) (Filer)

    8/6/25 3:18:51 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Company plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PERRIGO Co plc (0001585364) (Filer)

    8/6/25 6:37:52 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Financials

    Live finance-specific insights

    View All

    Perrigo to Release Third Quarter 2025 Financial Results on November 5, 2025

    DUBLIN, Oct. 22, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its third quarter 2025 financial results on Wednesday, November 5th, 2025, and host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 03742. A taped repla

    10/22/25 8:30:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Reports Second Quarter 2025 Financial Results From Continuing Operations

    Company Advanced its 'Three-S' Plan (Stabilize, Streamline, and Strengthen) with Recently Announced Agreement to Sell Dermacosmetics Business, Scaling of Global Operating Growth Model, and Upgraded Brand Building Capabilities that are Delivering Results Solid Execution Amid Challenging Market Consumption Trends Reaffirms Full Year 2025 Adj. EPS Target Range of $2.90 - $3.10 DUBLIN, Aug. 6, 2025 /PRNewswire/ --   Second Quarter 2025 YoY Highlights: Net Sales: $1.06 billion, down 0.9% year-over-year. Favorable currency translation (+1.7%) was more than offset by the impact of di

    8/6/25 6:30:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Announces Quarterly Dividend

    DUBLIN, July 30, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on September 16, 2025, to shareholders of record on August 29, 2025. About Perrigo   Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market, Pe

    7/30/25 12:55:00 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Perrigo Company plc

    SC 13G - PERRIGO Co plc (0001585364) (Subject)

    10/31/24 11:55:03 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Perrigo Company plc

    SC 13G - PERRIGO Co plc (0001585364) (Subject)

    2/13/24 1:05:29 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Perrigo Company plc (Amendment)

    SC 13G/A - PERRIGO Co plc (0001585364) (Subject)

    1/24/24 2:27:16 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care